Shelton Wealth Management LLC Has $1.07 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Shelton Wealth Management LLC boosted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 77.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,969 shares of the medical equipment provider’s stock after purchasing an additional 5,237 shares during the quarter. Shelton Wealth Management LLC’s holdings in Lantheus were worth $1,071,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LNTH. Wilmington Savings Fund Society FSB bought a new stake in Lantheus during the third quarter worth $25,000. Signaturefd LLC raised its holdings in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the last quarter. Nkcfo LLC bought a new position in shares of Lantheus during the second quarter valued at about $47,000. UMB Bank n.a. boosted its holdings in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new stake in Lantheus in the 3rd quarter worth about $51,000. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Down 0.1 %

LNTH stock opened at $91.47 on Friday. The stock has a market capitalization of $6.36 billion, a PE ratio of 15.22 and a beta of 0.46. The stock’s 50 day simple moving average is $89.72 and its 200 day simple moving average is $99.85. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group started coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. Finally, Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Insider Transactions at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.10% of the stock is currently owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.